Surmodics shares are trading higher after Needham upgraded the stock from Hold to Buy and announced a $36 price target.
Portfolio Pulse from Benzinga Newsdesk
Needham has upgraded Surmodics (SRDX) from Hold to Buy and set a $36 price target, causing the stock to trade higher.
June 13, 2023 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surmodics' stock is trading higher following Needham's upgrade from Hold to Buy and a $36 price target announcement.
The upgrade from Needham is a positive signal for Surmodics, as it indicates increased confidence in the company's prospects. The new price target of $36 also suggests potential upside for the stock, which is likely to attract more investors and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100